Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2020, 29(4):220-228

Role of adrenomedullin, galectin-3 and soluble ST2 in hypertensive patients at risk of heart failure

Huňavý M1, Jankajová M1, Gibarti C2, Pella D1, Gonsorčík J3
1 I. kardiologickej kliniky UPJŠ LF a VÚSCH a. s., Košice
2 Oddelenia rádiológie, VÚSCH a. s., Košice
3 II. kardiologickej kliniky UPJŠ LF a VÚSCH a. s., Košice, Slovenská republika

Background: Adrenomedullin (ADM), galectin-3 (Gal-3) and soluble ST2 (sST2) levels have been found elevated in heart failure (HF). Their relationship to coronary atherosclerosis and left ventricular hypertrophy (LVH) remains unclear. We evaluated the association of these biomarkers to the extent of coronary atherosclerosis and presence of LVH evaluated by multidetector computed tomography (MDCT) in hypertensive patients at risk of HF.

Methods: The study group consisted of 67 hypertensives indicated for MDCT coronary angiography who underwent echocardiography and plasma biomarker evaluation. 53 patienst had measurable for left ventricular mass indexed to body surface area (LVMIBSA). The presence of ≥ 50% diameter stenosis was considered significant and LVH by MDCT was defined as LVMIBSA > 79.2g/m2 in males and > 63.8g/m2 in females.

Results: Levels of Gal-3 were significantly higher in patients with coronary atherosclerosis compared to those without (11.09 ± 3.71 ng/ml vs. 8.71 ± 2.55 ng/ml; p=0.024). In multivariate logistic regression significant predictors of coronary atherosclerosis were levels of Gal-3 > 8.7 ng/ml (OR 3.71; 1.03 - 13.38; p=0.045). Patients with LVH had significantly higher levels of sST2 than patients without (20.94 ± 6.99 vs. 16.79 ± 5.26 ng/ml; p=0.019). In multivariate logistic regression, significant predictors of LVH on MDCT were diabetes mellitus (OR 7.06; 1.37 - 36.40; p=0.020) and sST2 (OR 1.14; 1.00 - 1.30; p=0.043).

Conclusion: Our results suggest the possible role of sST2 in pathophysiology of LVH, and galectin-3 as a marker of coronary atherosclerotic burden.

Keywords: atherosclerosis; computed tomography; adrenomedullin; galectin-3; soluble ST2

Published: April 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Huňavý M, Jankajová M, Gibarti C, Pella D, Gonsorčík J. Role of adrenomedullin, galectin-3 and soluble ST2 in hypertensive patients at risk of heart failure. Cardiology Letters. 2020;29(4):220-228.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-239.
    2. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2017;70:776803. Go to original source...
    3. Huňavý M, Gášpár P, Gonsorčík J. Prognostický význam adrenomedulínu, galektínu-3 a solubilného ST2 pri srdcovom zlyhávaní. Cardiology Lett. 2017;26:221-227.
    4. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-3104. Go to original source...
    5. Abbara S, Arbab-Zadeh A, Callister TQ, et al. SCCT guidelines for performance of coronary computed tomographic angiography: A report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr. 2009;3:190-204. Go to original source...
    6. Mao SS, Li D, Rosenthal DG, et al. Dual-standard reference values of left ventricular volumetric parameters by multidetector CT angiography. J Cardiovasc Comput Tomogr. 2013;7:234-240. Go to original source...
    7. Truong QA, Siegel E, Karakas M, et al. Relation of natriuretic peptides and midregional proadrenomedullin to cardiac chamber volumes by computed tomography in patients without heart failure: from the ROMICAT Trial. Clin Chem. 2010;56:651660. Go to original source...
    8. Bhandari SS, Davies JE, Struck J, Ng LL. The midregional portion of proadrenomedullin is an independent predictor of left ventricular mass index in hypertension. Metabolism. 2010;59:7-13. Go to original source...
    9. Neumann JT, Tzikas S, Funke-Kaiser A, et al. Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease. Atherosclerosis. 2013;228:451-459. Go to original source...
    10. Voors AA, Kremer D, Geven C, et al. Adrenomedullin in heart failure: pathophysiology and therapeutic application. Eur J Heart Fail. 2019;21:163-171. Go to original source...
    11. Dieplinger B, Januzzi JL Jr, Steinmair M, et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin Chim Acta. 2009; 409:33-40. Go to original source...
    12. Aksan G, Gedikli Ö, Keskin K, et al. Is galectin-3 a biomarker, a player - or both - in the presence of coronary atherosclerosis? J Investig Med. 2016; 64:764-770. Go to original source...
    13. Lisowska A, Knapp M, Tycińska A, et al. Predictive value of Galectin-3 for the occurence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study. Atherosclerosis. 2016;246:309-317. Go to original source...
    14. Ozturk D, Celik O, Satilmis S, et al. Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/ structure in patients with type 2 diabetes mellitus. Coronary Artery Dis. 2015;26:396-401. Go to original source...
    15. Menini S, Iacobini C, Ricci C, et al. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc Res. 2013;100:472-480. Go to original source...
    16. Demyanets S, Speidl WS, Tentzeris I, et al. Soluble ST2 and interleukin-33 levels in coronary artery disease: Relation to disease activity and adverse outcome. PLos ONE. 2014;9:e95055. Go to original source...
    17. Gopal DM, Larson MG, Januzzi JL, et al. Biomarkers of cardiovascular stress and subclinical atherosclerosis in the community. Clin Chem. 2014;60:1402-1408. Go to original source...
    18. Sinning C, Kieback A, Wild PS, et al. Association of multiple biomarkers and classical risk factors with early carotid atherosclerosis: results from the Gutenberg Health study. Clin Res Cardiol. 2014;103:477-485. Go to original source...
    19. Funke-Kaiser A, Havulinna AS, Zeller T, et al. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. Ann Med. 2014;46:155-162. Go to original source...
    20. Wild PS, Schnabel RB, Lubos E, et al. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AheroGene study. Clin Chem. 2012;58:226-236. Go to original source...
    21. Nicoll R, Wiklund U, Zhao Y, et al. The coronary calcium score is a more accurate predictor of significant coronary stenosis than conventional risk factors in symptomatic patients: Euro-CCAD study. Int J Cardio. 2016;207:13-19. Go to original source...
    22. Greenland P, Blaha MJ, Budoff MJ, et al. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72:434-447. Go to original source...
    23. Cho I, Hartaigh Ó, Gransar H, et al. Prognostic implications of coronary artery calcium in the absence of coronary artery luminal narrowing. Atherosclerosis. 2017;262:185-190. Go to original source...
    24. Gupta A, Lau E, Varshney R, et al. The Identification of Calcified Coronary Plaque Is Associated With Initiation and Continuation of Pharmacological and Lifestyle Preventive Therapies: A Systematic Review and Meta-Analysis. JACC Cardiovasc Imaging. 2017;10:833-842. Go to original source...
    25. Hecht H, Blaha MJ, Berman DS, et al. Clinical indications for coronary artery calcium scoring in asymptomatic patients: Expert consensus statement from the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr. 2017;11:157-168. Go to original source...
    26. Klein R, Ametepe ES, Yam Y, et al. Cardiac CT assessment of left ventricular mass in mid-diastasis and its prognostic value. Eur Heart J Cardiovasc Imaging. 2017;18:95-102. Go to original source...
    27. Budoff MJ, Ahmadi N, Sarraf G, et al. Determination of left ventricular mass on cardiac computed tomographic angiography. Acad Radiol. 2009;16:726-732. Go to original source...
    28. Sanada S, Hakuno D, Higging LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538-1549. Go to original source...
    29. Ojji DB, Opie LH, Lecour S, et al. The effect of left ventricular remodelling on soluble sST2 in a cohort of hypertensive subjects. J Hum Hypertens. 2014;28:432-427. Go to original source...
    30. Celic V, Majstorovic A, Pencic-Popovic B, et al. Soluble ST2 levels and left ventricular structure and function in patients with metabolic syndrome. Ann Lab Med. 2016;36:542-549. Go to original source...
    31. Van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;177:43-51. Go to original source...
    32. Gonçalvesová E. Srdcové zlyhávanie a diabetes mellitus. Nebezpečné spojenie. Cardiology Lett. 2020;29:9-16. Go to original source...
    33. Greupner J, Zimmerman E, Grohmann A, et al. Head-to-head comparison of left ventricular function assessment with 64-row computed tomography, biplane left cineventriculography, and both 2- and 3- dimensional transthoracic echocardiography: comparison with magnetic resonance imaging as the reference standard. J Am Coll Cardiol. 2012;59:1897-1907. Go to original source...
    34. Kara B, Nayman A, Guler I, et al. Quantitative assessment of left ventricular function and myocardial mass: A comparison of coronary CT angiography with cardiac MRI and echocardiography. Pol J Radiol. 2016;81:95-102. Go to original source...
    35. Wai B, Thai WE, Brown H, et al. Novel phase-based noise reduction strategy for quantification of left ventricular function and mass assessment by cardiac CT: comparison with cardiac magnetic resonance. Eur J Radiol. 2013;82:e337-341. Go to original source...
    36. Takx RA, Moscariello A, Schoepf UJ, et al. Quantification of left and right ventricular function and myocardial mass: comparison of low-radiation dose 2nd generation dual source CT and cardiac MRI. Eur J Radiol. 2012;81:e598-604. Go to original source...
    37. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines on the diagnosis and management of chronic coronary syndromes: the Task Force for diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019;1-71.doi:10.1093/eurheartj/ehz425. Go to original source...

    Return to the content